CellAura Signs Major Supply Deal with Cisbio Bioassays
News Oct 23, 2009
CellAura has announced a development partnership with Cisbio Bioassays. Under the terms of the agreement, CellAura will provide pharmacologically validated reagents to Cisbio Bioassays that will be applied to Cisbio Bioassays’ Tag-lite™ range of non-radioactive assays for cellular studies.
Commenting on the collaboration, CellAura CEO Dai Hayward said: "Maximizing cellular information is increasingly seen as the key to successful drug discovery. CellAura combines world-renowned expertise from the University of Nottingham in the fields of synthetic chemistry and molecular pharmacology to produce high quality fluorescent receptor ligands as key components in drug candidate screening assays and imaging techniques. This new partnership with Cisbio Bioassays, which is one of the leaders in bioassays for cell surface receptor and functional studies, recognizes our rapid progress and is a major milestone."
CellAura will develop a number of reagents for Cisbio Bioassays’ Tag-lite™ range. Tag-lite, part of Cisbio Bioassays’ comprehensive HTRF cellular platform, provides a homogeneous, non-radioactive and alternative for the study of cell surface receptor dimerization and ligand binding.
François Degorce, head of marketing for Cisbio Bioassays added: "GPCR and more generally cell surface receptor investigation are currently among the hottest topics in drug discovery. To enhance our Tag-lite platform addressing this area, we seek out partnerships with the best experts in their respective fields, and are pleased to collaborate with CellAura for the development of non-radioactive fluorescent ligands."
CellAura will also retain rights for the reagents developed for use in their own range of assays for certain markets. Financial details were not disclosed.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Prostate- and Colon Cancer Targeted With Tapeworm DrugNews
Recently researchers found that a substance in medicine against parasites like Giardia and Tapeworms, acts like tailored medicine against prostate- and colon cancer.READ MORE
New Player in Alzheimer's Disease Pathogenesis IdentifiedNews
Using proteomics, microscopic analysis, and functional assays, scientists have shown that a protein called membralin is critical for keeping Alzheimer’s disease pathology in check.READ MORE